Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma

Christina Sternberg1, Wolfgang Gruber1, Markus Eberl1, Suzana Tesanovic1, Manuela Stadler1, Dominik P. Elmer1, Michaela Schlederer2, Sandra Grund3, Simone Roos3, Florian Wolff4, Supreet Kaur1, Doris Mangelder1,4, Hans Lehrach5,6, Hendrik Hache5,6, Christoph Wierling5,6, Josef Laimer1, Peter Lackner1, Markus Wiederstein1, Maria Kasper7, Angela Risch1, Peter Petzelbauer8, Richard Moriggl9,10,11, Lukas Kenner2,3,9 and Fritz Aberger

1Department of Biosciences, Cancer Cluster Salzburg, Paris-Lodron University of Salzburg, Salzburg, Austria
2Clinical Institute of Pathology, Medical University of Vienna, Vienna, Austria
3Unit Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria
4CytoSwitch, Munich, Germany
5Department of Vertebrate Genomics, Max Planck Institute for Molecular Genetics, Berlin, Germany
6Alacris Theranostics GmbH, Berlin, Germany
7Department of Biosciences and Nutrition and Center for Innovative Medicine, Karolinska Institutet, Huddinge, Sweden
8Department of Dermatology, Medical University of Vienna, Vienna, Austria
9Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria
10Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, Vienna, Austria
11Medical University Vienna, Vienna, Austria

Persistent activation of hedgehog (HH)/GLI signaling accounts for the development of basal cell carcinoma (BCC), a very frequent nonmelanoma skin cancer with rising incidence. Targeting HH/GLI signaling by approved pathway inhibitors can provide significant therapeutic benefit to BCC patients. However, limited response rates, development of drug resistance, and severe side effects of HH pathway inhibitors call for improved treatment strategies such as rational combination therapies simultaneously inhibiting HH/GLI and cooperative signals promoting the oncogenic activity of HH/GLI. In this study, we identified the interleukin-6 (IL6) pathway as a novel synergistic signal promoting oncogenic HH/GLI via STAT3 activation. Mechanistically, we provide evidence that signal integration of IL6 and HH/GLI occurs at the level of cis-regulatory sequences by co-binding of GLI and STAT3 to common HH-IL6 target gene promoters. Genetic inactivation of IL6 signaling in a mouse model of BCC significantly reduced in vivo tumor growth by interfering with HH/GLI-driven BCC proliferation. Our genetic and pharmacologic data suggest that combinatorial HH-IL6 pathway blockade is a promising approach to efficiently arrest cancer growth in BCC patients.

Key words: basal cell carcinoma , GLI transcription factors , hedgehog, GLI signaling , interleukin-6 signaling , STAT transcription factors

Abbreviations: BCC: basal cell carcinoma; ChIP: chromatin immunoprecipitation; EDN2: endothelin 2; EGFR: epidermal growth factor receptor; ERK: extracellular signal-regulated kinase; GLI: glioma-associated oncogene; GSEA: gene set enrichment analysis; HH: hedgehog; IL6: interleukin-6; IL6R: interleukin-6 receptor; JAK: Janus tyrosine kinase; MEK: mitogen-activated protein/extracellular signal-regulated kinase kinase; NFkB: nuclear factor of kappa light polypeptide gene enhancer in B-cells; NRP1: neuropilin 1; OSM: oncostatin M; PI3K: phosphatidylinositol 3-kinase; PLAT: tissue plasminogen activator; PTCH: patched; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; shRNA: short hairpin RNA; SMO: smoothened; SMOi: smoothened inhibitor; STAT3: signal transducer and activator of transcription-3; TAM: tamoxifen; TYK2: tyrosine kinase-2

Additional Supporting Information may be found in the online version of this article.

Conflicts of Interest: The authors declare no conflict of interest.

Grant sponsor: University of Salzburg; Grant sponsor: Austrian Science Fund

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

DOI: 10.1002/ijc.31724

History: Received 29 Nov 2017; Accepted 22 Jun 2018; Online 10 July 2018

Correspondence to: Fritz Aberger, MSc, PhD, Cancer Cluster Salzburg, Department of Molecular Biology, University of Salzburg, Hellbrunner Strasse 34, 5020 Salzburg, Austria, E-mail: fritz.aberger@sbg.ac.at; Tel: +43-662-8044-5792, Fax: +43-662-8044-183

Markus Eberl’s current address is Department of Dermatology, University of Michigan, 48109 Ann Arbor, Michigan, USA

Supreet Kaur’s current address is Monash University, 3168 Clayton, Victoria, Australia

Int. J. Cancer: 143, 2943–2954 (2018) © 2018 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Persistent activation of hedgehog (HH)/GLI signaling represents the main driver signal for the development of basal cell carcinoma (BCC), a common non-melanoma skin cancer with rising incidence. Small molecule hedgehog pathway inhibitors are successfully used for the treatment of hedgehog-driven BCC, but frequent drug resistance calls for improved strategies. Here, the authors identified the interleukin-6 pathway as a novel synergistic signal promoting oncogenic HH/GLI via STAT3 activation. The synergistic interaction was required for the in vivo growth of hedgehog-driven BCC. The study thus provides a rationale for effective combination treatments simultaneously targeting oncogenic hedgehog and interleukin-6 signaling in BCC patients.

Basal cell carcinoma (BCC) is the most common cancer in the Western world with an annual incidence of 3–4 million new cases in the US alone. Genetic activation of the hedgehog (HH)/GLI pathway by inactivating mutations in the patched (PCH) gene or—more rarely—by activating mutations in the smoothened (SMO) gene represents the main driver signal in BCC pathogenesis. HH-mediated hyperactivation of the zinc finger transcription factors GLI1 and GLI2 results in a malignant expression profile driving tumor growth (Fig. 1a). Small-molecule SMO inhibitors (SMOi) show striking therapeutic efficacy in patients with advanced and metastatic BCC, though development of drug resistance and severe adverse effects leave many patients without proper treatment options. Furthermore, noncanonical, SMO-independent GLI activation has been identified as critical factor contributing to the growth of malignant cells refractory to SMOI treatment (reviewed in Refs. 12–15). Therefore, understanding the intricate molecular basis and genetic landscape of HH/GLI-driven skin cancer, including microenvironmental cues and interactions with the immune system, is key to the development of improved targeted therapies, particularly for BCC patients with a priori or acquired resistance to SMOI.

Inflammatory signals activated in cancer tissues are potent promoters of tumor initiation, progression and metastasis. Tumor-promoting inflammation is often mediated by the production of proinflammatory cytokines such as interleukin-6 (IL6) (reviewed in Refs. 17,18). IL6 signaling is triggered by ligand binding to the high-affinity IL6 receptor alpha (IL6R) subunit, which together with gp130 receptor subunits transduces the signal to the Janus tyrosine kinases (JAK1, JAK2 and TYK2). Upon JAK-mediated tyrosine phosphorylation of signal transduction and activator of transcription (STAT)-3, phospho-STAT3 (pSTAT3) dimerizes and translocates into the nucleus, where it engages its transcriptional regulatory function. STAT3 is the main transcription factor through which IL6 signals, although IL6 can lead also to the activation of MEK/ERK, PI3K/AKT or Nfkb signaling. IL6 can also be bound by a soluble form of the IL6R followed by subsequent interaction with gp130. This so-called IL6 trans-signaling allows IL6 to target cells not expressing the membrane-bound IL6R. The therapeutic relevance of IL6 signaling in malignant development is currently evaluated in a number of clinical trials with antibodies and small-molecule inhibitors targeting oncogenic IL6/STAT3 signaling. In light of the pivotal role of immunomodulatory cytokines and growth factors in the development and progression of malignancies, we performed in this study a candidate-based screen to identify possible enhancers of oncogenic HH/GLI signaling in the context of BCC development. We identified the proinflammatory IL6 pathway as a novel oncogenic cooperation partner of HH/GLI in BCC and show that HH/GLI and IL6/STAT3 signaling interact at the level of cis-regulatory elements of common HH-IL6 target genes. Using conditional genetic mouse models of BCC, we demonstrate that IL6 signaling is required for the formation of HH/GLI-driven BCC in vivo by synergistically promoting the proliferative effect of oncogenic HH/GLI signaling. Our study provides a rationale for combined inhibition of HH/GLI and IL6/STAT3 signaling for improved targeted therapy of BCC.

Material and Methods

Cell culture and treatments

Doxycycline (Dox)-inducible GLI1-expressing HaCaT keratinocytes and mouse BCC cell line ASZ001 were grown as described previously. Induction of GLI1 expression in HaCaT keratinocytes was done as reported in Refs. Murine NIH/3 T3 cells (AMS Biotechnology Ltd, Abingdon, UK) transduced with pBabe-puro-GLI1 or empty control vector were grown in Dulbecco’s modified Eagle medium (DMEM) (Sigma, St. Louis, MO) supplemented with 10% calf bovine serum (Sigma) and penicillin-streptomycin (Sigma). Chemicals and reagents used for cell treatments are listed in Supporting Information, Table S1. Recombinant human and mouse IL6 and Dox were used at a concentration of 50 ng/ml, unless indicated otherwise. For three-dimensional (3D) cultures, 1 × 10^6 human HaCaT keratinocytes were seeded in 12-well plates (Greiner Bio-one, Kremsmünster, Austria), cultured and analyzed in a blinded fashion as described previously.

qPCR and Western blot analysis

RNA isolation, cDNA synthesis and qPCR analysis of mRNA expression were carried as described previously. qPCR analysis was done on a Rotor–Gene Q (Qiagen, Hilden, Germany) using GoTaq qPCR Master Mix (Promega, Madison, WI).
sequences of primers used for amplification are listed in Supporting Information, Table S2. SDS-PAGE and Western blotting were performed according to standard protocols. Applied antibodies are listed in Supporting Information, Table S3.

**RNA interference and lentiviral transduction**

RNA interference and lentiviral transduction experiments were performed as described in Ref. 23. The following short hairpin RNA (shRNA) constructs selected from the Mission TRC shRNA library (Sigma) were used: shRNA IL6R#1 (TRCN0000378748), shRNA IL6R#2 (TRCN0000058780), shRNA JAK2#1 (TRCN000003180), shRNA JAK2#2 (TRCN000003181), shRNA STAT3#1 (TRCN0000071456), shRNA STAT3#2 (TRCN0000020843) and scrambled control shRNA (SHC002). Transduced cells were selected for puromycin resistance prior to further analysis.

**Analysis of cell proliferation**

Proliferation of human HaCaT keratinocytes with Dox-inducible GLI1 expression was analyzed with the Click-iT® Plus EdU Alexa Fluor® 555 Imaging Kit (Thermo Fisher Scientific, Waltham, MA). Cells were treated for 72 hr with Dox, IL6 and 1 μM panJAK-Inh I. EdU proliferation assay was performed according to the manufacturer’s instructions with the following modifications: Cells were incubated with 5 μM EdU for 3 hr. Cells were stained with Alexa Fluor® picolyl acid 555 and Hoechst® 33342, and counted in a blinded fashion. The ratio of proliferative cells to Hoechst-positive cells was calculated.

**Transgenic mice and allograft experiments**

K14creERT;Ptchfl/fl;Il6raf/f mice: K14CreERT (#5107), Ptchf/f (#12457) and Il6raf/ #12944) mice were genotyped according

---

Figure 1. IL6 synergizes with HH/GLI signaling in oncogenic transformation. (a) Schematic illustration of linear, canonical HH/GLI signaling in the absence of signal cross-talk. Loss-of-function mutations (LOF) in patched (PTCH) or gain-of-function mutations (GOF) in smoothened (SMO) account for the majority of BCC by releasing the GLI zinc-finger transcription factors from their inhibitor suppressor of fused (SUFU). Nuclear translocation of GLI activator forms (GLI*) leads to the onset of transcriptional activation of HH/GLI target genes. (b) Scheme of screen for oncogenic HH modifiers. Nontumorigenic, human HaCaT keratinocytes were grown in *in vitro* transformation assays and four conditions were tested: cells were either left untreated and served as solvent-only control (+solvent; GLI1), treated with cytokines or growth factors (+cytokine/growth factor; −GLI1), expressed GLI1 (+solvent; +GLI1) or a combination of both (+cytokine/growth factor; +GLI1). The number of transformed colonies served as readout. (b') Heat-map analysis of the *in vitro* screen for oncogenic HH modifiers. Changes in spheroid numbers are depicted relative to GLI1-expressing cells treated with solvent only (+solvent; +GLI1). Red color indicates a synergistic increase in the number of transformed colonies. (c) Quantitative results of *in vitro* transformation assays of human HaCaT keratinocytes after GLI1 activation in combination with or without IL6 treatment. (d) Quantitative results of *in vitro* transformation assay of GLI1 expressing mouse NIH/3T3 cells with or without IL6 treatment as indicated. Empty vector not expressing GLI1 served as control. (e) Quantitative results of *in vitro* transformation assay of SAG-responsive NIH/3 T3 cells upon SAG (100 nM) with or without IL6 stimulation as indicated. Statistical analysis by Student’s *t* test; ***p < 0.001; **p < 0.01.
to the supplier’s instructions (The Jackson Laboratory, Bar Harbor, ME). Tamoxifen (TAM) (Sigma) was dissolved in sunflower oil and administered at 1 mg/day by oral gavage to induce activation of Cre recombinase and knock-out of floxed alleles. All mice were treated with TAM on postnatal days p21–25, p46, p48 and p50 to achieve efficient recombination and euthanized on day p67, when the overall health condition of the mice declined and an established phenotype was observed (Supporting Information, Figs. S5c and S5d).

For in vivo tumor growth studies, $1 \times 10^6$ ASZ001 BCC cells with Stat3 knockdown (shStat3#1) or scrambled control shRNA were mixed with 25% Matrigel (BD Biosciences, San Jose, CA) and injected subcutaneously into nude mice (Charles River Laboratories, Wilmington, MA). Tumor volume was measured with a caliper and calculated according to the formula $[4/3 \times \pi \times (\text{length}/2) \times (\text{width}/2) \times (\text{height}/2)]$.

**Histology and immunohistochemistry**

Immunohistochemistry (IHC) was performed with formalin-fixed paraffin-embedded tissue using standard protocols and antibodies listed in Supporting Information, Table S3. Antibody detection was done using IDetect Super Stain System (IDlabs Biotechnology, Empire Genomics, Buffalo, NY). Staining was visualized using 3-amino-9-ethylcarbazole (IDlabs Biotechnology) under visual control. All images were taken with a Zeiss Axiosmager Z1, and quantification was performed with HistoQuest (TissueGnostics, Vienna, Austria). For tumor area determination, at least three different high-power fields per mouse of H&E-stained dorsal skin were analyzed and quantified. The tumor area of $Pitch$-deficient BCC mice with functional Il6ra was set to 100%.

**Microarray analysis and GSEA**

Genome-wide mRNA expression profiling was performed on a bead array technology platform (Illumina Inc., San Diego, CA). RNA of human HaCaT keratinocytes either expressing GLI1 (Dox treatment), treated with IL6 or stimulated with a combination of both was analyzed in comparison to untreated control cells. Gene set enrichment analysis (GSEA) was performed using GSEA software v3.0 (Broad Institute of MIT and Harvard, (http://software.broadinstitute.org/gsea/). For the identification of synergistically regulated HH-IL6 target genes, data obtained from microarray analysis were verified by qPCR analysis and the synergy score according to McMurray et al. was calculated. Synergy scores ≤0.9 defined target genes as synergistically induced in response to combined HH-IL6 stimulation.

**Promoter and histone modification studies**

_In silico_ prediction of putative GLI binding sites was done using the D-Light Software (genome sequence GRCh37/ hg19) trained with the GLI binding site matrix according to Winklmayr et al. The ENCyclopedia Of DNA Elements (ENCODE) Project was used to check for STAT3 binding regions. Luciferase reporter assays and site directed mutagenesis were carried out as described previously. All constructs were confirmed by sequencing.

Chromatin-immunoprecipitation (ChIP) assays were carried out as described previously. A total of 10 μg cross-linked chromatin was precipitated with antibodies listed in Supporting Information, Table S3. Immuneoprecipitated DNA was analyzed by qPCR on a Rotor-Gene Q (Qiagen) using GoTaq qPCR Master Mix reagent (Promega) with primers listed in Supporting Information, Table S2. The amount of immunoprecipitated DNA in each sample was calculated by the Percent Input Method according to the manufacturer’s instructions (Cell Signaling Technology, Boston, MA).

**Quantitative methylation analysis by bisulfite pyrosequencing**

Methylation status of a total of 9 CpG sites in adjacent GLI and STAT3 binding site regions of human EDN2 (NM_001956) was analyzed by bisulfite pyrosequencing. Genomic DNA (500 ng) was bisulfite-treated using the EZ DNA Methylation Kit (Zymo Research, Irvine, CA) according to manufacturer’s instructions. Bisulfite-converted DNA was PCR amplified using HotStar Taq Polymerase (Qiagen) with the primers listed in Supporting Information, Table S4. GLI binding sites were biotin-tagged with a universal sequence (see Supporting Information, Fig. S4f). Pyrosequencing was performed on the PyroMark Q24 Advanced System (Qiagen).

**Statistical analysis**

Significant differences between two groups were determined using a two-tailed, unpaired t test. $p$ values of <0.05 were assigned significance and $p$ values are considered as follows: $^* p<0.05$, $^{**} p<0.01$ and $^{***} p<0.001$. All values are given as means ± standard error of the mean (s.e.m.) and were analyzed by GraphPad Prism (GraphPad Software, San Diego, CA). Numbers of animals are stated in the respective figure legends.

**Ethics**

Human BCC tissue arrays for immunohistochemistry analyses were used in accordance with the guidelines of the Austrian ethics committee application (EK405/2006, extension 11/10/2016). Animal experiments and care were carried out in accordance with the guidelines of institutional authorities and approved by the Federal Ministry of Science, Research and Economy (BMWF-66.012/0017-II/3b/2012, BMWFW-66.012/0016-WF/V/3b/2015).

**Results**

IL6 synergizes with HH/GLI1 in oncogenic transformation

To test for immunomodulatory cytokines and/or growth factors able to cooperate with HH/GLI signaling (Fig 1a) in oncogenic transformation, we used nontumorigenic, human keratinocytes (HaCaT) with doxycycline-inducible GLI1 expression. Importantly, GLI1 expressing keratinocytes do
not display a fully transformed phenotype but require additional cooperative signals for malignant growth. We took advantage of this characteristic and performed a candidate-based in vitro transformation screen for immunomodulatory cytokines and growth factors that are able to cooperate with HH/GLI in the process of oncogenic transformation. As read-out for oncogenic transformation we monitored clonal growth in 3D anchorage-independent settings, which we have previously shown to correlate with in vivo tumor growth (Fig 1b). In total, we have screened 13 secreted factors, of which seven factors passed the preselection criteria, including detectable expression of the cognate receptor as judged by RNaseq data (Human Protein Atlas www.proteinatlas.org) and the ability to induce the activation of established downstream effectors (Supporting Information, Table S5). As positive control for the integrity of the screen, we monitored cellular transformation by concomitant epidermal growth factor (EGF) signaling and GLI1 expression, which we have previously shown to have potent synergistic transformation capacity (Fig 1b). As shown in Figures 1b and 1c, GLI1 expression and simultaneous treatment with the proinflammatory cytokine IL6 resulted in a synergistic increase in the number of transformed colonies in 3D anchorage-independent assays compared to single treatments. Neither of the other soluble signaling factors tested was able to enhance the oncogenic transformation efficiency of GLI1. We also observed synergistic transformation of Hh-responsive mouse NIH/3T3 fibroblasts upon combined Gli1 expression and Il6 treatment (Fig 1d) and upon combined treatment with the HH pathway activator smoothened agonist (SAG) and Il6 (Fig 1e). Together, these data identify IL6 signaling as a novel synergistic interaction partner of HH/GLI in oncogenic transformation.

IL6 signals through IL6R/JAK2/STAT3 to cooperate with oncogenic HH/GLI signaling

Next, we aimed to identify the IL6-induced downstream signaling cascade that integrates with HH/GLI in the synergistic transformation of epidermal cells. IL6 can signal through the activation of MEK/ERK, PI3K/akt or JAK/STAT3, the latter representing the canonical intracellular signal relay mechanism (Fig 2a). As shown in Figure 2b and Supporting Information, Figure S1b, IL6 treatment of human HaCaT keratinocytes resulted in the JAK-dependent phosphorylation of STAT3 (pSTAT3) but failed to activate PI3K/akt and MEK/ERK signaling. This clearly differentiates the mechanism of HH-IL6 synergy from the previously described synergism of HH/GLI and EGRF signaling, which involves MEK/ERK/JUN activation downstream of EGRF.

To identify the respective IL6 signal effectors in HH-IL6-mediated oncogenic transformation, we performed systematic pharmacologic and genetic inhibition experiments (see overview in Fig 2a and Supporting Information, Fig S1 for validation of the functionality of inhibitors and short hairpin RNAs (shRNAs)). As shown in Figure 2c, shRNA-mediated knockdown of the receptor subunit IL6R (shIL6R) prevented synergistic transformation of human HaCaT keratinocytes in response to combined activation of IL6 and HH/GLI signaling. In line with the protein data shown in Figure 2b, treatment with panJAK-Inh 1 resulted in a significant reduction of synergistic oncogenic transformation in response to combined IL6-GLI1 activation (Fig. 2d). To identify the respective signal-mediating JAK involved in the HH-IL6 cooperation, we first targeted TYK2 and JAK2 using selective kinase inhibitors Bayer-18 and lestaurtinib, respectively. Treatment with the TYK2 inhibitor Bayer-18 did not abrogate the transformed phenotype, whereas the JAK2 inhibitor lestaurtinib efficiently prevented colony formation (Fig. 2d). We corroborated the essential role of JAK2 by genetic targeting with two independent shRNAs (shJAK2#1 and shJAK2#2). In line with chemical JAK2 perturbation, knockdown of JAK2 significantly diminished HH-IL6-dependent oncogenic transformation (Fig. 2e). To address the involvement of STAT3 downstream of IL6/JAK2, we blocked STAT3 pharmacologically and genetically. The small-molecule STAT3 inhibitor STATTIC35 (Fig. 2f) and depletion of STAT3 expression using shSTAT3 (Fig. 2g) both resulted in a significant reduction of HH-IL6 induced transformation. Consistently, also treatment of Il6-stimulated/Gli1 expressing NIH/3T3 cells (Supporting Information, Fig. S2a) or Il6/SAG-stimulated NIH/3T3 cells (Supporting Information, Fig S2b) with panJAK-Inh I or lestaurtinib impaired Hh-Il6 driven oncogenic transformation. Taken together, our data show that oncogenic HH-IL6 signal cooperation requires activation of the IL6R/JAK2/STAT3 signaling cascade.

HH/GLI-IL6/STAT3 cross-talk cooperatively regulates gene expression by signal integration at the level of cis-regulatory elements of common HH-IL6 target genes

Next, we aimed to decipher the molecular mechanisms underlying oncogenic HH-IL6 signal cooperation, first by testing for possible reciprocal modifications of signaling activities at multiple regulatory levels. We examined if STAT3 modifies GLI1 protein stability, expression or nuclear localization, but found no evidence for that (Supporting Information, Figs. S3a–S3d). Vice versa, GLI1 expression neither affected the intracellular localization of STAT3 (Supporting Information, Fig. S3d) nor STAT3 activation in response to IL6 signaling (Supporting Information, Fig. S3e). We therefore hypothesized that cell transformation induced by cooperating oncogenic signals is caused by synergistic modulation of gene expression via signal integration at the level of cis-regulatory regions of common HH-IL6 target genes, analogous to our previous findings of HH-EGFR signal cooperation. To test this hypothesis, we performed illumina bead array-based transcriptomics of human HaCaT keratinocytes with either active HH/GLI1, IL6/STAT3 or a combination of both. We identified genes synergistically regulated by combined HH-IL6 signaling.
Figure 2. IL6/JAK2/STAT3 signaling cooperates with HH/GLI in oncogenic transformation. (a) Illustration of IL6 signaling and downstream pathway activation. Binding of IL6 to its receptor can activate at least three downstream signaling cascades: JAK/STAT3, MEK/ERK/JUN and PI3K/AKT signaling. In the context of malignant transformation, IL6 induces JAK/STAT3 activation. The genetic and pharmacologic approaches to inhibit IL6 signaling effectors are depicted. (b) Western blot analysis of GLI1 expressing human HaCaT keratinocytes treated with IL6, or 10 ng/ml EGF. β-tubulin served as loading control. Fine black lines indicate cropping of intermediate lanes from the same Western blots. p, phospho; t, total; (c–g) Quantitative analysis of in vitro transformation assays using HaCaT keratinocytes. Cells were treated either with solvent, Dox to induce GLI1, IL6 or Dox and IL6. Additionally, double-stimulated cells (+GLI1;+IL6) were treated as follows: (c) with shRNA against IL6R (shIL6R, shRNA #1 in Supporting Information, Fig. S1a), (d) with panJAK-Inh I (1 μM), Bayer-18 (100 nM and 300 nM) or lestaurtinib (100 nM and 300 nM), (e) with shRNA constructs against JAK2 (shJAK2#1, shJAK2#2), (f) with STAT3C (1 μM) or (g) with shRNA against STAT3 (shSTAT3). ns, not significant; shcont, scrambled nontarget control shRNA; Statistical analysis by Student’s t test; ***p < 0.001; *p < 0.05.
where synergistic regulation was defined by synergy score values of ≤0.9 (see Ref. 28). From the list of synergistically regulated HH-IL6 target genes we selected endothelin 2 (EDN2), neuropilin 1 (NRP1) and tissue-type plasminogen activator (PLAT) as representative genes highly expressed in BCC (Supporting Information, Fig. S4a) and used these HH-IL6 regulated genes as molecular readout to decipher the mechanisms of signal integration (Fig. 3a). Intriguingly, we found that transcriptional activation of the known HH/GLI target gene PTCH was unaffected by simultaneous IL6 signaling (Supporting Information, Fig. S4b), suggesting that IL6 does not simply boost the expression of HH/GLI target genes but—in combination with HH/GLI—selectively activates a distinct set of common HH-IL6 targets. Having shown that oncogenic transformation induced by combined HH-IL6 signaling depends on activation of IL6R/JAK2/STAT3 signaling activity, we first tested whether synergistic HH-IL6 target gene regulation also involves these IL6 effectors. In line with our data on oncogenic transformation by combined HH-IL6 signaling, RNAi-mediated inhibition of IL6R, JAK2 or STAT3 effectively abrogated the expression of the HH-IL6 target genes EDN2, NRP1 and PLAT (Fig. 3b).

We next tested the hypothesis that selective activation of HH-IL6 target genes involves co-binding of GLI1 and STAT3 transcription factors to the cis-regulatory region of HH-IL6 targets. Interestingly and as depicted in Figure 3c, all three HH-IL6 target genes harbor putative GLI and STAT3 binding sites in close proximity as predicted by bioinformatics analysis. By contrast, in silico analysis of the PTCH promoter revealed GLI binding sites 30, but failed to identify STAT3 binding sites (Supporting Information, Fig. S4c), consistent with PTCH expression being insensitive to IL6 signaling. To analyze binding of GLI1 and STAT3 to HH-IL6 target gene promoters, we performed chromatin immunoprecipitation (ChIP) of GLI1 and STAT3 and found that both transcription factors bind to the predicted binding sites in the representative HH-IL6 target genes (Fig. 3d).

To corroborate the ChIP data, we cloned the promoter region of the HH-IL6 target PLAT and performed luciferase reporter assays to analyze the functionality of the GLI and STAT3 binding sites in the respective cis-regulatory region. Site directed single and combined mutagenesis of the GLI and STAT3 binding sites in the PLAT promoter confirmed the requirement of both binding sites for full-blown promoter activation (Supporting Information, Fig. S4d).

Furthermore, we analyzed possible epigenetic changes triggered by combined HH-IL6 signaling. ChIP analysis of activating histone modifications revealed an increase in H3K27 acetylation upon combined HH/GLI and IL6/STAT3 activity when compared to single pathway activity (Supporting Information, Fig. S4e). As combined HH/GLI-IL6/STAT3 signaling did not affect the DNA methylation status (see Supporting Information, Fig. S4f), we conclude that cooperation of GLI and STAT3 does not depend on changes in CpG methylation.

Together, our data suggest a mechanistic model, where HH-IL6 signal integration involves simultaneous binding of HH-induced GLI and IL6-induced STAT3 transcription factors to the cis-regulatory region of common HH-IL6 target genes.

IL6 signaling is required for in vivo growth of HH/GLI-driven BCC

We next addressed the in vivo relevance of HH-IL6 synergism in HH/GLI-driven BCC. As a first approach, we analyzed by immunohistochemistry (IHC) human and murine BCC for expression of IL6 effectors such as IL6R and STAT3. In line with a putative oncogenic role of IL6 signaling in HH/GLI-driven BCC, we found expression of both proteins in human and mouse BCC tissue (Fig. 4a and Supporting Information, Fig. S5a). Of note, human BCC display prominent IL6R expression on the cell surface of palisading BCC cells. Consistently, we also detected active, nuclear STAT3 staining in this tumor area. In addition, marked expression of IL6ra and nuclear Stat3 was detected in mouse BCC-like lesions (Supporting Information, Fig. S5a and Supporting Information), supporting a crucial role for IL6 signaling in HH-induced skin carcinogenesis.

To address a possible functional contribution of IL6 signaling to HH/GLI-driven BCC, we genetically inactivated IL6 signaling in a conditional mouse model of human BCC. For this purpose, we crossed Keratin14creERT2;Ptch+/f (PtchΔf/f) mice, which develop BCC lesions upon tamoxifen (TAM)-induced, epidermal-specific Ptch deletion, 37 with mice harboring a conditional, floxed Il6ra allele (Il6raΔf/f) 38 to generate BCC mice with an additional tumor-specific deletion of Il6ra (PtchΔf/f; Il6raΔf/f) (Fig. 4b). As shown in Figure 4c, PtchΔf/f;Il6raΔf/f mice developed numerous BCC-like lesions. Intriguingly, mice with concomitant deletion of Il6ra (PtchΔf/f;Il6raΔf/f) presented significantly smaller lesions compared to Il6ra-proficient mice (Fig. 4c). Quantification of tumors grown revealed a 50% reduction of the relative tumor area in the epidermis of PtchΔf/f;Il6raΔf/f mice compared to PtchΔf/f;Il6ra+/+ controls (Fig. 4d).

To also address the role of STAT3 in HH/GLI-driven BCC growth, we depleted by RNAi the expression of Stat3 in murine Ptch-deficient BCC cells and compared the in vivo growth of Stat3-deficient BCC cells with that of Stat3-proficient controls. As shown in Figure 4c, shRNA-mediated knockdown of Stat3 expression significantly reduced the in vivo growth of murine BCC cells (Fig. 4e and Supporting Information, Fig. S5b).

Together with our in vitro studies on oncogenic transformation, these data suggest that IL6/STAT3 cooperates with HH/GLI signaling to promote BCC growth.

Cooperation of HH/GLI and IL6 signaling promotes epidermal proliferation

Based on the pronounced expression of IL6R and STAT3 in the peripheral growth zone of human BCC and the
Figure 3. Integration of HH-IL6 signaling at cis-regulatory regions of common HH-IL6 target genes. (a) mRNA expression analysis by qPCR of selected HH-IL6 target genes (EDN2, NRP1, PLAT) in human HaCaT keratinocytes in response to Dox-induced GLI1 expression, IL6 treatment or a combination of both. Synergy (syn) score values of ≤0.9 indicate synergistic cooperation of simultaneous HH-IL6 signaling. (b) qPCR mRNA expression analysis of HH-IL6 target genes in human HaCaT keratinocytes in response to GLI1 expression, IL6 stimulation and additional knockdown of IL6R (shIL6R#1, shIL6R#2), JAK2 (shJAK2#1, shJAK2#2) or STAT3 (shSTAT3#1, shSTAT3#2). Signals are relative to double-stimulated cells transduced with shcont, scrambled nontarget shRNA; shcont, scrambled nontarget control shRNA; *** p < 0.001; (c) in silico analysis of the cis-regulatory region of selected HH-IL6 target genes (EDN2, NRP1, PLAT) for the presence of STAT3 binding regions and putative GLI binding sites. Numbers show the start position of GLI binding sites (blue) and STAT3 binding regions (red) relative to the transcriptional start site (TSS). (d) ChIP analysis of selected HH-IL6 target genes (EDN2, NRP1, PLAT) for GLI1 (left) and STAT3 binding (right). Human HaCaT keratinocytes expressing Dox-inducible MYC-tagged GLI1 treated with IL6 were analyzed. Mouse IgG (mlgG) or rabbit IgG (rlgG) served as negative controls.
requirement of Il6ra and Stat3 for efficient in vivo growth of mouse BCC, we hypothesized that cooperation of IL6 and HH/GLI may promote proliferation of BCC. We therefore analyzed by IHC the skin of PtchΔep;Il6raΔep and PtchΔep;Il6ra+/+ mice for the proliferation marker Ki67. In BCC lesions of PtchΔep;Il6ra+/+ mice, Ki67 positive cells were distributed throughout the tumor tissue (Fig. 5a). By contrast, in the dorsal skin of PtchΔep;Il6raΔep mice, the proliferative Ki67-positive cells were restricted to the basal layer of the skin, similar to the normal proliferation pattern of healthy skin. To corroborate the putative proliferative role of HH/GLI and IL6 cooperation, we also performed in vitro proliferation studies using GLI1 expressing human HaCaT keratinocytes as a model for epidermal proliferation. Consistent with an enhancement of epidermal proliferation by HH-IL6, combined activation of GLI1 and IL6 signaling significantly increased keratinocyte proliferation compared to single treatments (Figs. 5b and 5c). Perturbation of the HH-IL6 cooperation with the panJAK-Inh I resulted in significantly decreased proliferation as assessed by EdU labeling. In addition, gene set enrichment analysis (GSEA) of HH-IL6-regulated mRNA expression revealed cell cycle and DNA replication genes to be significantly enriched in the target gene set, further supporting a proliferative role of HH-IL6 signaling in BCC development (Fig. 5d). In summary, our findings suggest a model where HH-IL6 cooperation at the level of common target...
genes promotes BCC growth by enhancing tumor cell proliferation (Fig. 5e).

Discussion
Aberrant activation of HH/GLI signaling plays an etiologic role in a wide variety of human cancer entities and despite several setbacks in clinical trials, targeting HH/GLI remains a promising treatment strategy with the potential for curative effects by eradicating cancer stem cells involved in tumor initiation, metastasis and drug resistance.\textsuperscript{14\textendash}39 Despite the remarkable therapeutic benefits of SMOi in BCC, development of resistance, severe adverse effects and recurrence after cessation of drug treatment\textsuperscript{42\textendash}44 highlight the need for novel strategies that not only focus on HH inhibition but also take into account interacting pathways modulating the oncogenicity of HH signaling.

Although genetic and epigenetic alterations within cancer cells are the main drivers of malignant development, it has recently become clear that intricate reciprocal interactions of cancer cells with the tumor microenvironment and the
immune system are pivotal for malignant progression. In this study, we performed a candidate-based screen for immune-related modifiers of oncogenic HH/GLI signaling and identified a striking tumor promoting role of the proinflammatory cytokine IL6 in HH/GLI-driven oncogenic transformation and BCC development. We show that synergistic transformation by HH/GLI-IL6 signaling relies on IL6/JAK2-mediated activation of STAT3. In this context, it is intriguing to note that combined stimulation with Oncostatin M (OSM) and HH/GLI failed to induce transformation despite strong STAT3 activation upon OSM treatment (Fig. 1b’). Whether the inability of OSM signaling to cooperate with HH/GLI is due to for instance distinct signal strength, duration, STAT heterodimerization or parallel activation of tumor suppressive processes is unclear and needs to be addressed in future studies.

Our genetic, ChIP- and reporter assay based analyses suggest that HH-IL6 signal integration involves concomitant binding of IL6-activated STAT3 and GLI activator forms such as GLI1 to the cis-regulatory regions of HH-IL6 target genes, thereby driving selective and synergistic activation of target gene expression. We have also shown that HH-IL6 signal integration cooperatively enhances epidermal proliferation, suggesting that simultaneous HH-IL6 signaling supports tumor growth by synergistically activating a proliferative expression profile. This is in agreement with the genetic inactivation of Il6ra and Stat3 function in murine models of BCC as well as with the respective in situ expression of IL6 effectors in human BCC, which together support the pathophysiological and clinical relevance of our findings. Whether the protumorigenic effect of combined HH-IL6 signaling is directly mediated by the HH-IL6 targets EDN2, PLAT and NRP1 requires further functional studies. In this context, it is noteworthy that PLAT and NRP1 play a well-documented role in angiogenesis, in line with previous reports about a putative angiogenic function of IL6 in BCC.7-9 However, as we did not detect a decrease in CD31+ endothelial cells in Il6ra-deficient mouse BCC (data not shown), it appears rather unlikely that HH-IL6 signal integration drives BCC growth by supporting tumor angiogenesis.

This study also raises the question about the source of IL6. Paracrine IL6 signaling may emanate for instance from macrophages,10 though the precise immune cell status of established BCC has not yet been characterized in detail. As an alternative to paracrine IL6 signaling, activation of HH/GLI may itself stimulate the production of IL6 in the cancer cells. Indeed, we have previously shown that activation of GLI2 enhances the expression of IL6 in epidermal cells.26 Also, GLI1 has been shown to directly induce IL6 expression in stromal cells of pancreatic adenocarcinomas lesions, triggering paracrine STAT3 activation in the tumor cell compartment.49 Whether IL6 signaling is activated by oncogenic HH/GLI within the tumor cell compartment or communicated to BCC via the tumor microenvironment, infiltrating immune cells or via sIL6R-mediated trans-signaling remains to be addressed in future studies.

The possible therapeutic relevance of our findings is further underlined by the promising efforts to develop efficacious anti-IL6/JAK/STAT3 drugs for the treatment of various solid and hematopoietic malignancies. Small-molecule inhibitors or antagonistic antibodies targeting critical effectors of IL6 signaling including IL6 itself, IL6r, gp130, JAK1/JAK2 and STAT3 have recently been approved or are currently evaluated in several clinical trials with patients suffering from cancer entities with a documented involvement of HH/GLI signaling such as breast and non-small-cell lung cancer (for review, see Refs. 17,21,50 and references therein).

The identification of the IL6/JAK/STAT3 signaling cascade as a cooperative partner in HH/GLI-associated cancers provides a new rationale for evaluating combined HH-IL6 targeting in BCC to improve the therapeutic efficacy of SMO inhibitor treatments.

Acknowledgements

The authors are grateful to Drs Alexandra Kaser and Sandra Laner-Plamberger for providing inducible MYC-tagged GLI1 cell lines and to Professor Andrzej Dlugosz for K5Cre;Cbsg2 mice. This work was supported by the Austrian Science Fund (PFW projects P25629, P26052 and W1213 to FA, and SFB F4707-B20 and SFB-F06105 to RM), the Austrian Genome Project Gen-AU (FFG project MoGli to FA), the county of Salzburg (research grants 20102-P150461-FPR02-2015, 20102-P1601064-FPR01-2016 to FA) and the priority program “Allergy–Cancer–Bionano Research Center” of the University of Salzburg. MK was supported by the Swedish Cancer Society. The authors acknowledge the use of GSEA software and Molecular Signature Database (MSigDB)27 (http://www.broad.mit.edu/gsea/).

References

1. Sekulic A, Von Hoff D. Hedgehog pathway inhibition. Cell 2016;164:831.
2. Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer 2008;8:743–54.
3. Hahn H, Wicking C, Zaphiropoulous PG, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1998;85:41–51.
4. Xie J, Murone M, Luoh SM, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998;391:90–2.
5. Johnson RL, Rothman AL, Xie J, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996;272:1668–71.
6. Kasper M, Regl G, Frischau AM, et al. GLI transcription factors: mediators of oncogenic hedgehog signaling. Eur J Cancer 2006;42:437–45.
7. Tang JY, Alpy MS, Chanana AM, et al. Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology 2016;17:1720–31.
8. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012;366:2171–9.
9. Atwood SX, Sarin KY, Whitson RJ, et al. Smoother variants explain the majority of drug resistance in basal cell carcinoma. Cancer Cell 2015;27:542–53.
10. Basset-Seguin N, Sharpe HJ, de Sauvage FJ. Efficacy of hedgehog pathway inhibitors in basal cell carcinoma. Mol Cancer Ther 2015;14:633–41.
11. De Smaele E, Ferretti E, Gulino A. Vismodegib, a small-molecule inhibitor of the hedgehog pathway for the treatment of advanced cancers. Curr Opin Investig Drugs 2010;11:707–18.
12. Tepland S, Togtgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochem Biophys Acta 1805;2010:181–208.
Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma

13. Lauth M, Toftgard R. Non-canonical activation of GLI transcription factors: implications for targeted anti-cancer therapy. *Cell Cycle* 2007;6:2458–63.

14. Abberger F, Ruiz IAA. Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy. *Semin Cell Dev Biol* 2014;33:93–104.

15. Pandolfo S, Stecca B. Cooperative integration between HEDGEHOG-GLI signaling and other oncogenic pathways: implications for cancer therapy. *Exp Rev Mol Med* 2015;17:e5.

16. Bonilla X, Parmentier I, King B, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. *Nat Genet* 2016;48:398–406.

17. Aberger F, Ruiz IAA. Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy. *Cell Cycle* 2007;6:2458–63.

18. Shalapour S, Karin M. Immunity, in *Cytokine Growth Factor Rev* 2015;26:475–87.

19. Lauth M, Toftgard R. Non-canonical activation of GLI signaling and its regulation. *Biochem J* 2003;374:1–20.

20. Eberl M, Klingler S, Mangelberger D, et al. Epidermal growth factor receptor signaling synergizes with hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. *Cancer Res* 2009;69:1284–92.

21. Regl G, Kasper M, Schnidar H, et al. The zinc-finger transcription factor GLI2 antagonizes contact inhibition and differentiation of human epidermal cells. *Oncogene* 2004;23:1263–74.

22. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA* 2005;102:15545–50.

23. McMurray HR, Sampson ER, Compitello G, et al. Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma. *Nat Med* 2002;8:1575–8.

24. Laimer J, Zuzan CJ, Ehrenberger T, et al. D-Light module of smoothened activity. *Proc Natl Acad Sci USA* 2005;102:1575–8.

25. Schaper F, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem J* 2003;374:1–20.

26. Schuster J, Sperl B, Hollis A, et al. Stattic: a small-molecule inhibitor of STAT3 activation and its regulation. *Semin Cell Dev Biol* 2015;26:475–87.

27. Aberger F, Ruiz IAA. Context-dependent signal integration by the GLI code: the oncogenic load, pathways, modifiers and implications for cancer therapy. *Cell Cycle* 2007;6:2458–63.

28. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

29. Laimer J, Zuzan CJ, Ehrenberger T, et al. D-Light module of smoothened activity. *Proc Natl Acad Sci USA* 2005;102:1575–8.

30. Tanger J, Zuzan CJ, Ehrenberger T, et al. D-Light on promoters: a client-server system for the analysis and visualization of cis-regulatory elements. *BMC Bioinformatics* 2013;14:140.

31. Kondrashov A, Gokhman Y, Lin D, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

32. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

33. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

34. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

35. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

36. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

37. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

38. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

39. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

40. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

41. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

42. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

43. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

44. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

45. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

46. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

47. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

48. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

49. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.

50. Wang F, Liu Y, Gao Y, et al. The role of STAT3 in cancer. *Int J Mol Med* 2012;30:1005–12.